Vaccinoprophylaxis of infections and activity of immuno-inflammatory rheumatic diseases: pro et contra
https://doi.org/10.37489/0235-2990-2024-69-1-2-65-73
EDN: CYIUUW
Abstract
In modern conditions, patients with immuno-inflammatory rheumatic diseases (IIRD) are at significant risk of influenza, pneumococcal and herpes viral infections, as well as COVID-19, in some cases fatal. The most effective way to prevent infectious diseases and reduce mortality from them is vaccination, which is recommended in the inactive phase of IIRD. However, a number of patients with IIRD have a refractory course of the disease, and achieving remission in them turns out to be a difficult task, and therefore the problem of vaccination of such patients against the background of an active inflammatory process is very relevant. The review analyzes data on the use of vaccine prophylaxis for the above infections in the active phase of IIRD. In the vast majority of cases, vaccination was safe and did not lead to an exacerbation of IIRD or the development of new autoimmune phenomena.
About the Authors
B. S. Belov
V. A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Boris S. Belov — D. Sc. in Medicine, Head of the Laboratory of Comorbid Infections and Vaccine Prevention
34A Kashirskoe highway, V. A. Nasonova Research Institute of Rheumatology, Moscow, 115522
ResearcherID: ABD-22192020. Scopus Author ID: 7004592537
N. V. Muravyeva
V. A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Natalia V. Muravyeva — Ph. D. in Medicine, Senior Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention
Moscow
ResearcherID: AAF-4853-2021. Scopus Author ID: 57210263706
References
1. Furer V, Rondaan C., Heijstek M., van Assen S., Bijl M. Agmon-Levin N. et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. doi: 10.1136/rmdopen-2019-001041.
2. Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584 (7821): 430–436. doi: 10.1038/s41586-0202521-4.
3. Joo Y.B., Kim K.J., Park K.S., Park Y.J. Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization. Sci Rep. 2021; 11 (1): 4630. doi: 10.1038/s41598-021-84153-5.
4. Nasonov E.L., Belov B.S., Lila A.M., Aronova E.S., Gridneva G.I., Kudryavtseva A.V. et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Rheumatology Science and Practice. 2021; 59 (6): 666–675. doi: https://doi.org/10.47360/1995-4484-2021-666-675. (in Russian)]
5. Felten R., Scherlinger M., Guffroy A., Poindron V., Meyer A., Giannini M. et al. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Res Ther. 2021; 23 (1): 188. doi: 10.1186/s13075-021-02565-0.
6. Furer V., Rondaan C., Heijstek M.W., Agmon-Levin N., van Assen S., Bijl M. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.
7. Chang C.C., Chang Y.S., Chen W.S., Chen Y.H., Chen J.H. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016; 6: 37817. doi: 10.1038/srep37817.
8. Kobashigawa T., Nakajima A., Taniguchi A., Inoue E., Tanaka E., Momohara S., Yamanaka H. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013; 42 (6): 445–50. doi: 10.3109/03009742.2013.788733.
9. Del Porto F., Laganà B., Biselli R., Donatelli I., Campitelli L., Nisini R. et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006; 24 (16): 3217–3223. doi: 10.1016/j.vaccine.2006.01.028.
10. Elkayam O., Bashkin A., Mandelboim M., Litinsky I., Comaheshter D., Levartovsky D. et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010; 39 (6): 442–447. doi: 10.1016/j.semarthrit.2008.12.002.
11. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010; 62 (1): 75–81. doi: 10.1002/art.25033.
12. Ribeiro A.C., Guedes L.K., Moraes J.C., Saad C.G., Aikawa N.E., Calich A.L. et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011; 70 (12): 2144–2147. doi: 10.1136/ard.2011.152983.
13. Gabay C., Bel M., Combescure C., Meier S., Posfay-Barbe K., Grillet S., et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011; 63 (6): 1486–1496. doi: 10.1002/art.30325.
14. Borba E.F., Saad C.G., Pasoto S.G., Calich A.L., Aikawa N.E., Ribeiro A.C. et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology. 2012; 51 (6): 1061–1069. doi: 10.1093/rheumatology/ker427.
15. Lu C.C., Wang Y.C., Lai J.H., Lee T.S., Lin H.T., Chang D.M. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine. 2011; 29 (3): 444–450. doi: 10.1016/j.vaccine.2010.10.081.
16. Bukhanova D.V., Belov B.S., Tarasova G.M., Erdes Sh., Dubinina T.V., Lukina G.V. et al. Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases. Meditsinskiy Sovet = Medical Council. 2018; (12): 106–110. doi: https://doi.org/10.21518/2079-701X-2018-12-106-110. (in Russian)]
17. Campos L.M., Silva C.A., Aikawa N.E., Jesus A.A., Moraes J.C., Miraglia J. et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res. 2013; 65 (7): 1121–1127. doi: 10.1002/acr.21948.
18. Huang Y., Wang H., Tam W.W.S. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr Med Res Opin. 2017; 33 (10): 1901–1908. doi: 10.1080/03007995.2017.1329140.
19. Huang Y. Wang H., Wan L., Lu X., Tam W.W.S. Is Systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016; 9 5(19): e3637. doi: 10.1097/MD.0000000000003637.
20. Backhaus E., Berg S., Andersson R., Ockborn G., Malmström P., Dahl M., et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016; 16: 367. doi: 10.1186/s12879-016-1648-2.
21. Luijten R.K., Cuppen B.V., Bijlsma J.W., Derksen R.H. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014; 23: 1512-1516. doi:10.1177/0961203314543918.
22. Tarasova G.M., Belov B.S., Reshetnyak T.M., Cherkasova M.V. Vaccination of pneumococcal infection in patients with systemic lupus erythematosus and antiphospholipid syndrome: experience of 6 years of use. Rheumatology Science and Practice. 2023; 61 (3): 330–338. doi: https://doi.org/10.47360/1995-4484-2023-330-338. (in Russian)]
23. Belov B.S., Muravyova N.V., Tarasova G.M., Baranova M.M. Vaccination against pneumococcal infection in rheumatology: retrospective and modernity. Effective Pharmacotherapy. 2022; 18 (8): 32–40. doi: https://doi.org/10.33978/2307-3586-2022-18-8-32-40. (in Russian)]
24. Migita K., Akeda Y., Akazawa M., Tohma S., Hirano F., Ideguchi H. et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015; 17: 357. doi: 10.1186/s13075-015-0863-3.
25. Winthrop K.L., Bingham C.O. 3rd, Komocsar W.J., Bradley J., Issa M., Klar R., Kartman C.E. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019; 21 (1): 102. doi: 10.1186/s13075-019-1883-1.
26. Bingham C.O. 3rd, Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010; 62 (1): 64–74. doi: 10.1002/art.25034.
27. Naumtseva M.S., Belov B.S., Aleksandrova E.N., Tarasova G.M., Novikov A.A., Karateev D.E., et al. Assessment of the immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2015; 53 (6): 586–590. doi: http://dx.doi.org/10.14412/1995-4484-2015-586-590. (in Russian)]
28. Baranova M.M., Muravyeva N.V., Belov B.S., Verizhnikova Zh.G. Experience with 23-valent pneumococcal polysaccharide vaccine in patients with ankylosing spondylitis and psoriatic arthritis. Medical Alphabet. 2023; (31): 15–20. doi: https://doi.org/10.33667/2078-5631-2023-31-15-20. (in Russian)]
29. Pugès M., Biscay P., Barnetche T., Truchetet M.É., Richez C., Seneschal J. et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology. 2016; 55 (9): 1664–1672. doi: 10.1093/rheumatoogy/kew211.
30. Curtis J.R., Yang S., Chen L., Winthrop K., Xie F., Baddley J.W. et al. Herpes Zoster Infection across Auto-Immune and Inflammatory Diseases: Implications for Vaccination. Ann Rheum Dis. 2014; 73: Suppl 2: 452. doi: 10.1136/annrheumdis-2014-eular.5983.
31. Singer D., Thompson-Leduc P., Poston S., Gupta D., Cheng W.Y., Ma S. et al. Incidence of Herpes Zoster in patients with rheumatoid arthritis in the United States: A Retrospective Cohort Study. J Rheumatol. 2023; 50 (7): 873–880. doi: 10.3899/jrheum.220986.
32. Esteban-Vazquez A., Steiner M., Castañeda E., Andreu-Vazquez C., Thiussard I.J., Somodevilla A. et al. The real-world study of immunogenicity and safety of the adjuvant recombinant vaccine against Varicella Zoster Virus in patients with immune-mediated inflammatory diseases treated with janus kinase inhibitors. Vaccines (Basel). 2023; 11 (10): 1610. doi: 10.3390/vaccines11101610.
33. Stevens E., Weinblatt ME., Massarotti E., Griffin F., Emani S., Desai S. Safety of the Zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: A single center's experience with 400 patients. ACR Open Rheumatol. 2020; 2 (6): 357–361. doi: 10.1002/acr2.11150.
34. Gupta S., Arasaratnam R.J., Solow E.B., Bajaj P. A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease. J Clin Rheumatol. 2022; 28 (2): e528– e531. doi: 10.1097/RHU.0000000000001790.
35. Lenfant T., Jin Y., Kirchner E., Hajj-Ali R.A., Calabrese L.H., Calabrese C. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology. 2021; 60 (11): 5149–5157. doi: 10.1093/rheumatology/keab139.
36. Tzioufas A.G., Bakasis A.D., Goules A.V., Bitzogli K., Cinoku I.I., Chatzis L.G. et al. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun. 2021; 125: 102743. doi: 10.1016/j.jaut.2021.102743.
37. Rotondo C., Cantatore F.P., Fornaro M., Colia R., Busto G., Rella V. et al. Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A twocenters study. Vaccines (Basel). 2021; 9 (7): 730. doi: 10.3390/vaccines9070730.
38. Izmirly P.M., Kim M.Y., Samanovic M., Fernandez-Ruiz R., Ohana S., Deonaraine K.K. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022; 74 (2): 284–294. doi: 10.1002/art.41937.
39. Connolly C.M., Ruddy J.A., Boyarsky B.J., Barbur I., Werbel W.A., Geetha D. et al. Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol. 2022; 74 (1): 28–32. doi: 10.1002/art.41924.
40. Yoshida T., Tsuji H., Onishi A., Takase Y., Shirakashi M., Onizawa H. et al. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022; 9 (1): e000727. doi: 10.1136/lupus-2022-000727.
41. Machado P.M., Lawson-Tovey S., Strangfeld A., Mateus E.F., Hyrich K.L., Gossec L. et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022; 81 (5): 695–709. doi: 10.1136/annrheumdis-2021-221490.
42. van Dam K.P.J., Wieske L., Stalman E.W., Kummer L.Y.L., Roosen J., van Kempen Z.L.E. et al. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. J Autoimmun. 2023; 135: 102984. doi: 10.1016/j.jaut.2022.102984.
43. Felten R., Kawka L., Dubois M., Ugarte-Gil M.F., Fuentes-Silva Y., Piga M., Arnaud L. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021; 3 (9): e613–e615. doi: 10.1016/S2665-9913(21)00221-6.
44. Belov B. S., Lila A. M., Nasonov E. L. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022; 60 (1): 21–31. doi: https://doi.org/10.47360/1995-4484-2022-21-31. (in Russian)]
45. Bass A.R., Chakravarty E., Akl E.A., Bingham C.O., Calabrese L., Cappelli L.C. et al. 2022 American College of Rheumatology Guideline for Vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023; 75 (3): 449–464. doi: 10.1002/acr.25045.
46. Curtis J.R., Johnson S.R., Anthony D.D., Arasaratnam R.J., Baden L.R., Bass A.R. et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023; 75 (1): E1-E16. doi: 10.1002/art.42372.
Review
For citations:
Belov B.S., Muravyeva N.V. Vaccinoprophylaxis of infections and activity of immuno-inflammatory rheumatic diseases: pro et contra. Antibiot Khimioter = Antibiotics and Chemotherapy. 2024;69(1-2):65-73. (In Russ.) https://doi.org/10.37489/0235-2990-2024-69-1-2-65-73. EDN: CYIUUW
Views:
381
Email this article 